ATE257513T1 - Neuartige marker maligner zelltypen in der inneren nukleären matrix - Google Patents

Neuartige marker maligner zelltypen in der inneren nukleären matrix

Info

Publication number
ATE257513T1
ATE257513T1 AT93916829T AT93916829T ATE257513T1 AT E257513 T1 ATE257513 T1 AT E257513T1 AT 93916829 T AT93916829 T AT 93916829T AT 93916829 T AT93916829 T AT 93916829T AT E257513 T1 ATE257513 T1 AT E257513T1
Authority
AT
Austria
Prior art keywords
cell types
malignant cell
nuclear matrix
inner nuclear
markers
Prior art date
Application number
AT93916829T
Other languages
English (en)
Inventor
Gary Toukatly
Graham P Lidgard
Original Assignee
Matritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matritech Inc filed Critical Matritech Inc
Application granted granted Critical
Publication of ATE257513T1 publication Critical patent/ATE257513T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Microscoopes, Condenser (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93916829T 1992-06-22 1993-06-21 Neuartige marker maligner zelltypen in der inneren nukleären matrix ATE257513T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90170192A 1992-06-22 1992-06-22
PCT/US1993/006160 WO1994000573A1 (en) 1992-06-22 1993-06-21 Novel malignant cell type markers of the interior nuclear matrix

Publications (1)

Publication Number Publication Date
ATE257513T1 true ATE257513T1 (de) 2004-01-15

Family

ID=25414663

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93916829T ATE257513T1 (de) 1992-06-22 1993-06-21 Neuartige marker maligner zelltypen in der inneren nukleären matrix

Country Status (9)

Country Link
US (5) US5783403A (de)
EP (1) EP0647270B1 (de)
JP (1) JPH07509602A (de)
AT (1) ATE257513T1 (de)
AU (1) AU681855B2 (de)
CA (1) CA2138807A1 (de)
DE (1) DE69333377T2 (de)
ES (1) ES2214476T3 (de)
WO (1) WO1994000573A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230890T2 (de) * 1991-10-31 2000-12-07 Matritech, Inc. Bestimmung von nukleären matrixproteinen in flüssigkeiten
EP0684955B1 (de) * 1993-02-09 2005-08-24 The Johns Hopkins University School Of Medicine Zellkernmatrixproteine
US6280956B1 (en) 1995-11-03 2001-08-28 University Of Pittsburgh Antibodies to bladder cancer nuclear matrix proteins and their use
AU7474696A (en) * 1995-11-03 1997-05-22 Robert R. Bahnson Bladder nuclear matrix proteins and their use in detecting and treating cell proliferative disorders
US5914238A (en) * 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
US5858683A (en) 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6232443B1 (en) * 1997-04-08 2001-05-15 University Of Pittsburgh Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use
US7021122B1 (en) 1998-03-19 2006-04-04 Orgenics Biosensors Ltd. Device for the determination of blood clotting by capacitance or resistance
US6287790B1 (en) * 1998-11-30 2001-09-11 The Regents Of The University Of California Utilization of nuclear structural proteins for targeted therapy and detection of proliferative and differentiation disorders
EP1826569A1 (de) 1999-05-17 2007-08-29 Cytyc Corporation Identifizierung von Material aus Brustgängen
US6617432B1 (en) 1999-10-15 2003-09-09 University Of Pittsburgh Nuclear matrix proteins polynucleotide sequences encoding them and their use
US20030228640A1 (en) 1999-10-15 2003-12-11 University Of Pittsburgh Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
SE523665C2 (sv) * 2002-09-20 2004-05-11 Volvo Technology Corp Bränslecell och bränslecellsstack
WO2005062708A2 (en) * 2003-12-29 2005-07-14 Ramot At Tel-Aviv University Ltd. An assay for the detection of rapamycin and rapamycin analogs
DE102004052729A1 (de) * 2004-10-30 2006-05-04 Roche Diagnostics Gmbh Immunkomplex-spezifsicher Antikörper zur Reduktion des Nullwerts beim Nachweis von Antigen-spezifisch gebundenen Antikörpern einer bestimmten Immunglobulinklasse in Array-Testformaten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882268A (en) * 1985-12-24 1989-11-21 Massachusetts Institute Of Technology Method for determining tissue of origin and degree of malignancy of tumor cells
US5273877A (en) * 1985-12-24 1993-12-28 Massachusetts Institute Of Technology Non-histological cell type determination
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
DK0527941T3 (da) * 1990-05-01 1996-10-07 Isis Pharmaceuticals Inc Identifikation af hidtil ukendte lægemidler og reagenser
DE69230890T2 (de) * 1991-10-31 2000-12-07 Matritech, Inc. Bestimmung von nukleären matrixproteinen in flüssigkeiten

Also Published As

Publication number Publication date
US5780596A (en) 1998-07-14
ES2214476T3 (es) 2004-09-16
DE69333377T2 (de) 2004-10-21
US5686562A (en) 1997-11-11
AU4655093A (en) 1994-01-24
EP0647270A1 (de) 1995-04-12
US5882876A (en) 1999-03-16
US5698439A (en) 1997-12-16
WO1994000573A1 (en) 1994-01-06
CA2138807A1 (en) 1994-01-06
AU681855B2 (en) 1997-09-11
JPH07509602A (ja) 1995-10-26
US5783403A (en) 1998-07-21
DE69333377D1 (de) 2004-02-12
EP0647270B1 (de) 2004-01-07

Similar Documents

Publication Publication Date Title
ATE257513T1 (de) Neuartige marker maligner zelltypen in der inneren nukleären matrix
Kastan et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells
Sarkar et al. Receptors for human gamma interferon: binding and crosslinking of 125I-labeled recombinant human gamma interferon to receptors on WISH cells.
Coffino et al. Immunoglobulin production: method for quantitatively detecting variant myeloma cells
DE69836956D1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
ATE295416T1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
ATE314462T1 (de) Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
Cheung et al. New collagen markers of ‘derepression’synthesized by rabbit articular chondrocytes in culture
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
MXPA02008239A (es) Gen humano de la esquizofrenia.
DE69434470D1 (de) Zellkernmatrixproteine
MXPA03010523A (es) Anticuerpos especificos para cd44v6.
DE69533464D1 (de) Verfahren zur Herstellung von rekombinanten menschlichen LH-RH Rezeptor Proteinen in spezifischen CHO Zellinien.
EP0566571A4 (de) Diagnose von krebs-metastasen durch das mts-1 gen.
Cinader et al. An alpha-globulin allotype in the mouse (MuB 1)
ATE265533T1 (de) Saeugetierchemokine
Rosen et al. Human placenta contains an epithelial scatter protein
Shih et al. Identification of neighbor relationships among proteins in the 30 S ribosome: intermolecular cross-linkage of three proteins induced by tetranitromethane
EP0833948A4 (de) Für den dickdarm spezifische gene und proteine
NO985742L (no) IL-1/TNF-<alfa>-aktivert kinase (ITAK) og fremgangsmÕter for fremstilling og anvendelse av denne
SCHAUDIES et al. Intracellular modification of 125I-labeled epidermal growth factor by normal human foreskin fibroblasts
ATE130757T1 (de) Adhäsionsrezeptor für laminin und dessen verwendung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties